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a b s t r a c t
The delivery of nanoparticles through receptor-mediated cell interactions has nowadays a major atten-
tion in the area of drug targeting applications. This specific kind of targeting is mediated by localized
receptors impeded into the target site with subsequent drugs internalization. Hence, this type of interac-
tion would diminish side effects and enhance drug delivery efficacy to the target site. Somatostatin recep-
tors (SSTRs) are one type of G protein-coupled receptors, which could be active targeted for various
purposes. There are five SSTRs types (SSTR1-5) which are localized at various organs in the body and
spread into different tissues. SSTRs could be considered as a promising target to various nanoparticles
which is facilitated when nanoparticles are modified through specific ligand or coating to allow better
binding. This review discusses the exploration of SSTRs for active targeting of nanoparticles with certain
emphasize on their interaction at the cellular level.
 2018 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The nanoparticles represent good model candidates in the field
of drug delivery applications. This could be due to many reasons
such as they could be prepared in an ideal size suitable for cell
internalization and active targeting, facilitated conjugation with
various biomaterials and other molecules without changing the
biological activity of the conjugated compounds. However, there
are some issues should be considered to deliver these nanoparti-
cles to their active sites such as resistance against photobleaching
(Chen et al., 2009), enhanced stability presented on an acceptable
blood circulation time (Ballou et al., 2005). As well as surface mod-
ification to enhance their binding to certain receptors (Abdellatif
et al., 2016).
Metallic nanoparticles e.g., gold nanoparticles, (AuNPs), and sil-
ver nanoparticles (AgNPs), and quantum dots, Qdots encapsulated,
adsorbed or conjugated to different types of drugs could be easily
targeted to specific sites in the human body (Akhter et al., 2011).
These nanoparticles could be prepared and stabilized using differ-
ent types of polymers and linkers such as an 11-
mercaptoundecanoic acid (11-MUA) and polyethylene glycol
(Abdellatif et al., 2016; Alibakhshi et al., 2017). Moreover, the
development of metallic nanoparticles is fast and multidirectional,
and the developed prospective metallic nanoparticle highlights
their effectiveness as a new field for forthcoming cancer therapeu-
tics modalities (Ahmad et al., 2010). Furthermore, they could be
conjugated with somatostatin (SST) or its analogs such as octreo-
tide, OCT, as SSTRs agonist, or SSTRs antagonist ligand for active
targeting (Surujpaul et al., 2008; Elbakry et al., 2009; Alibakhshi
et al., 2017).
Addition of PEG to different types of nanomaterials will
improve the biological and physiochemical activities as well as
enhancing the circulation time in blood allowing them to reach
the specific target sites (Na and DeLuca, 2005; Park and Na,
2008; Abdellatif, 2015). PEG also sheath the nanoparticles with a
hydrophilic layer which prevents the opsonization process and
resist the non-specific phagocytosis (Zhang et al., 2011; Tawfeek,
2013). Moreover, the PEGylation of nanoparticles preserved and
stabilize the final formulated of nanoparticles (Na et al., 2003; Na
and DeLuca, 2005; Abdellatif, 2015).
Drug targeting enhance effectiveness, declines adverse effects,
and limits systemic drug exposures. The active targeting is usually
chosen to bind surface molecules or receptors that are over-
expressed in tissues, surface cells or at subcellular level
(Abdellatif, 2015; Abdellatif et al., 2016; Ramzy et al., 2017). In
addition, active targeting avoids the non-specific internalization
through the cell membrane, which affects the targeting efficiency
of nanoparticles. This may be enhanced by changing the physio-
chemical properties such as the density of ligand, and the dimen-
sions of the formulated nanoparticles or to the choice of the
involved targeting ligand in vitro as well as in vivo (Abdellatif,
2015; Alibakhshi et al., 2017; Ramzy et al., 2017).
A great advantage of Qdots over organic fluorophores is that
Qdots are resistant to photobleaching (Chen et al., 2009), have long
circulation time and are stable in the blood circulation for several
months (Ballou et al., 2005). Nevertheless, limited cytotoxicity
results from their Cd content (Chen et al., 2012; Ye et al., 2012).
In addition, Qdots carrying PEG-amine showed low cytotoxicity
when applied to cell culture (Zhang et al., 2006).
Lower acute toxicity has been observed for Qdots in vivo, when
rhesus macaques were injected with phospholipid micelle-
encapsulated CdSe/CdS/ZnS Qdots, the clearance of Qdots was very
slow (Ye et al., 2012). Injection of Qdots into tumor-bearing nude
mice indicated that they could be used as fluorescent probes for
in vivo imaging to study the bio-distribution of nanocarriers and
their intracellular pathways. Furthermore, Qdots-loaded micelles
accumulated in the tumor tissue in a passive way (Cao et al., 2012).
Tumor cells can be killed by excitation of internalized AuNPs
(Kang et al., 2010). Ligands-decorated AuNPs can also target special
receptors in the human body, i.e. AuNPs capped with peptide Cys-
Leu-Pro-Phe-Phe-Asp (CLPFFD) interacted with the transferrin
receptor present in the microvascular endothelial cells of the
blood-brain barrier (Prades et al., 2012). Furthermore, AuNPs were
delivered to ovarian cancer cells that express the epidermal growth
factor receptor and the folate receptor than the other single-
receptor-targeting systems (SRTS) (Bhattacharyya et al., 2011).
Many studies showed that nanoparticles linked specific ligands
or monoclonal antibodies could be targeted to surface receptors
over-expressed by cancer cells, such as the SSTRs, the folate recep-
tor, and transferrin receptors, can increase cellular internalization
of any drug through endocytosis process and improve the effec-
tiveness of systemic anticancer therapy. Furthermore, nanoparti-
cles coated cell-penetrating peptides and protein-transduction
domains, such as oligoarginine and TAT facilitated the uptake of
these nanoparticles which cannot successfully enter cancer cells
(Abdellatif et al., 2016).
This review points out the active targeting of nanoparticles
compared to the passive targeting approaches. In passive targeting,
the medication’s achievement is directly related to the time at
which the active entity still present in circulation. This approach
could be manipulated via covering nanoparticles with some kind
of coating. Numerous materials can accomplish this task, with
some of them being polyethylene glycol (PEG). By addition PEG
to the external surface of nanoparticles, it is becoming hydrophilic.
Hence, permitting water molecules to bind with the oxygen mole-
cules on PEG via hydrogen bonding. The product of this kind of
hydrogen bonding is considered to form a film of the hydrated
layer across NP, stealth nanoparticles, which builds the substance
antiphagocytic. Hence, the drug-coated nanoparticle is able to stay
in circulation for a longer period. However, this kind of mechanism
needs tight control of nanoparticles size and distribution. PEGy-
lated nanoparticles could be also used for active specific targeting
after being conjugated with a suitable targeting moiety. Neverthe-
less, the nanoparticles will be in much bigger size, which prevents
the non-specific binding through the cell membrane. Actually,
nanoparticles within 10 and 100 nm in size are postulated to be
present in circulation for a longer time (Sonia et al., 2017).
Nowadays, there is a numerous trials for combing several char-
acters in one materials to form what is called the multifunctional
nanomaterials. They could be used for diagnosis, specific targeting
drug therapy as well as monitoring therapeutic response. Despite
the several advantages of these nanomaterials, toxicity is still an
issue and a big challenge, which needs lot of efforts to overcome
(Rahman et al., 2012a, 2012b, 2012c).
In this review, a promising receptor site for active targeting of
nanoparticles and the interaction of nanoparticles conjugated with
specific targeting peptides, i.e. SST and OCT with these receptors
have been addressed. In addition, challenges regarding the delivery
of these nanoparticles linked peptides and their cellular uptake
into different cell lines have been also discussed.
2. G protein-coupled receptors
G protein-coupled receptors (GPCRs) are the biggest family of
seven transmembrane domain receptors in mammalian species
and are responsible for communication between a cell and its envi-
ronment (Pierce et al., 2002). They play the main role in many dis-
eases such as cancer and are also the target of numerous drugs
such as somatostatin and integrin receptors (Auld et al., 2002).
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Different kinds of molecules can activate GPCRs, such as ions,
amino acids (i.e. Glutamate, Ca2+) and GABA. Many peptides and
large molecule proteins, i.e. chemokine, angiotensin, thrombin,
and others, can also activate GPCRs. Biogenic amines i.e. nora-
drenaline, 5HT, histamine, acetylcholine also can interact with
GPCRs. GPCRs can be activated with low nanomolar concentrations
followed by rapid tissue intracellular responses to regulate cell
function and to exhibit a cell response (Fig. 1a) (Kobilka, 2007).
These receptors control many physiological processes in the mam-
malian species e.g., immune system, central nervous system regu-
lation, all hormones, and enzymes released and/or inhibited from
endocrine or exocrine glands (i.e. SSTRs), sympathetic and
parasympathetic regulations, and smell senses (Fig. 1b) (Hazell
et al., 2012).
The GPCRs carboxyl terminal is located in the cytosol. It plays a
specific role in G-protein coupling whereas the N-terminal amino
group is localized in the extracellular space (Oliveira et al., 1993).
So, these receptors are regulated by many different ligands. Upon
ligand binding to GPCRs, they undergo different types of changes.
This interaction catalyzes the GDP-GTP exchange on the Ga pro-
teins, then Ga is dissociated from Gbc subunits. Both aGTP sub-
units and Gbc sub-units complexes then stimulate other
intracellular proteins (Neves et al., 2002). The usual pathway of
Gas is to activate adenylate cyclase which catalyzes the conversion
of ATP to cyclic-AMP. The high concentration of cAMP may then
increase the Ca2+ release from endoplasmic reticulum (Fig. 1c)
(Wettschureck and Offermanns, 2005).
Conversely, stimulation of the Gai/o type inhibits adenylate
cyclase to synthesize cAMP. Briefly, the role of GPCR coupled to
Gai/o counteract the actions of a GPCR coupled to Gas, and vice
versa (Neves et al., 2002). Interaction of Gaq activates PLC. A phos-
pholipid then cleaved from PLC. DAG and IP3 cleaved from PIP2.
IP3 released into the cytosol. IP3 then diffuses through the cytosol
to bind to IP3 receptors, particularly calcium channels in ER. These
channels allow the release of Ca2+ into the cytosol and lead to an
increase of intracellular Ca2+. Many of GPCRs that couple to
Ga12/13 also couple to other classes, often Gaq/11 (Neves et al.,
2002). The pathway of G12 and G13 is still unclear; it could be a
direct interaction with a GTPase-activating protein for Ras, or Bru-
kon´s tyrosine kinase. GTPase can bind to GTP, and Rho activates
other proteins which are responsible for cytoskeleton regulation
such as Rho kinase, (Fig. 1c) (Jiang et al., 1998; Shi et al., 2001).
GPCRs can be known as an excellent target for many drugs. Recent
studies have reported that many GPCRs, such as chemokine
Fig. 1. Schematic drawing of the molecular interactions of G-protein coupled receptors and the actions of small and large molecules on GPCRs, a & b) Regulation of systemic
functions by signaling through G protein pathways, c). GPCRs interact with heterotrimeric G proteins (a, b and c subunits). Agonist binding triggers change in the receptor
that catalysis the dissociation of GDP from the subunit followed by GTP-binding to Ga and the dissociation of Ga from Gbc subunits. Schematic drawing modified from (Neves
et al., 2002; Dorsam and Gutkind, 2007).
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receptors (Singh et al., 2010; Nimmagadda, 2012), endothelin
receptors (Jia et al., 2008; Liakou et al., 2012), TSH receptor
(Antonelli et al., 2008; Torosian et al., 2010), LH receptors
(Szepeshazi et al., 2007), lysophosphatidic acid receptors
(Dorsam and Gutkind, 2007), SSTRs (Msaouel et al., 2009;
Luboldt et al., 2010; Oddstig et al., 2011; Sun and Coy, 2011;
Treglia et al., 2012), estrogen receptors (Deroo and Korach, 2006),
are expressed in cancers (Dorsam and Gutkind, 2007).
2.1. Somatostatin receptors
SSTRs are members of the GPCRs superfamily (Hoyer et al.,
1995; Patel, 1999). There are classified to five different subtypes
of (SSTR1–5), furthermore, SSTR2 have been classified into two dif-
ferent subtypes, SSTR2A and SSTR2B (Taniyama et al., 2005; Rufini
et al., 2006). The five receptor subtypes bind with the natural SST
and its analogs at low nanomolar concentration and produce
defined biological effects in normal and diseased cells (Patel,
1999). The blocking of receptors with antagonist suppresses the
interaction of the peptide agonist (Long, 1988). It was reported that
SSTRs are expressed in numerous normal and diseased cells, such
as the pituitary gland, salivary glands, cerebellum, monocytes,
parathyroid, thyroid, activated lymph nodes, vessels, lymphocytes,
macrophages, spleen, duodenum, gastric mucosa, ileum, colon,
pancreas, blood, bronchial gland, testes, ovary, and myocardium
(Abdellatif et al., 2016). SSTR2A expressed in the brain, pituitary
gland, islet of Langerhans, stomach, and kidney (Reubi et al.,
2001; Taniyama et al., 2005). SSTRs are also expressed in many
tumor cells i.e., small cell lung cancer (Virgolini et al., 2002;
Rivera et al., 2005; Weiner and Thakur, 2005), neuroendocrine
tumors (Appetecchia and Baldelli, 2010), breast cancer, prostate
cancer (Sharma and Srikant, 1998), colorectal carcinoma
(Reynaert et al., 2004; Ahmad et al., 2013). SSTR2 is expressed in
glucagonoma (Zacharias et al., 2005), metastatic lymph nodes
(Behr et al., 1997), insulinoma (Wente et al., 2005; Zacharias
et al., 2005; Roosterman et al., 2008), normal adrenal gland,
pheochromocytoma (Kubota et al., 1994). The majority of human
cancer cells (benign or malignant), are generally positive for SSTRs
(Patel, 1997). They are characterized by the changing their surface
receptors (McMahon et al., 2009). So, targeting of SSTRs, especially
SSTR2, would be a promising target for nanoparticulate delivery
systems (Nilsson et al., 1998). According to the latest market sur-
vey, numerous nanocarrier drug delivery systems were approved
by USFDA, EMEA, MHRA and other global controlling organiza-
tions. Where as many other nanocarrier drug delivery products
are under the preclinical and clinical progress phases (Rahman
et al., 2012a, 2012b, 2012c; Aneja et al., 2014; Rahman et al., 2014).
2.2. Somatostatin and its analogs
SST and its analogs are qualified by altering the SST gene
expression by stimulating GPCRs through a Gi/o-coupled receptor.
Steady-state SSTRs mRNA concentrations are stimulated by various
ligands which in turn minimize adenylate cyclase, forms cAMP,
and can regulate several subsets of K+ channels, voltage-
dependent Ca2+, guanylate cyclase, phospholipase C, phospholipase
A2 and PTP (Kubota et al., 1996; Huang et al., 2006). Stimulation of
SSTRs reduces Ca2+ concentration and intracellular cAMP levels.
The interaction between SSTRs with some Ca2+ and K+ channels
is presented in Fig. 2 (Patel, 1999).
SST has various functions in mammals such as it regulates the
secretion of growth hormones (Moaeen-Ud-Din and Yang, 2009).
Furthermore, it is widely distributed throughout the central ner-
vous system and peripheral tissues and plays different roles in
the central nervous system (Bell et al., 1995; Reisine et al., 1995).
SST prevents the regulation of numerous endogenous cell func-
tions, such as modulation of neurotransmission, cell motility, cell
proliferation and cell secretion (Florio et al., 1994; Lahlou et al.,
2004). The amino acids sequence and structure of SST are shown
in Figs. 3 and 4. SST soluble in water at a concentration of 6 mg/
mL. Phenylalanine (Phe) (6&7), tyrosine (Try 8), and lysine (Lys
9) are essential amino acids for the biological activity of SST
(Lamberts et al., 1996). However conjugation or deletion of Phe
Fig. 2. Schematic drawing of the molecular interaction of SST and its analogs on G protein inhibitory. SST and its analogs are capable of altering the SST gene expression by
stimulating GPCRs through a Gi/o-coupled receptor. Schematic drawing modified from (Neves et al., 2002; Dorsam and Gutkind, 2007).
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or Lys 4 results in reducing the binding affinity of OCT (Rosenthal
et al., 1983; Hirst and Coy, 1984).
2.3. Octreotide (OCT)
OCT is an SST analog and a shorter peptide, it has 8 amino acids.
The sequence of amino acids is shown in Figs. 5 and 6. It is soluble
in water and 1% acetic acid solution at a concentration of 6 mg/mL.
It selectively interacts and targets SSTR2, SSTR5, especially more
selective to SSTR2 and less selective to SSTR3. The plasma half-
life of OCT is much higher than that of the endogenous SST. OCT
had an apparent half-life of 1.7–1.9 h compared to 1–3 min with
SST (Watt et al., 2008). Many studies reported that OCT was deliv-
ered to cancer cells expressed SSTRs (Dasgupta, 2004). SST analogs
have been widely used to target tumor cells expressing SSTRs using
radionuclides such as 90-Y or 177-Lu (Nayak et al., 2005). SST ana-
logs were labeled with a radionuclide (i.e. 111-In, 90-Y, 177-Lu, 68-
Ga) and injected intravenously, they showed a reduction of tumor
growth (Reubi, 2003). Radio-materials labeled SST analogs, i.e.
glucose-Tyr3-octreotide and DOTA-Tyr3-octreotide were used for
the biological imaging and treatment of tumor cells expressed
SSTRs (Petrik et al., 2007). Recently, OCT was conjugated to micel-
lar nanoparticles for the targeting of specific tumor cells (Zhang
et al., 2011; Zhang et al., 2012).
PEGylation of OCT showed improvement in its biological and
physiochemical properties and demonstrate longer circulation
time (Na and DeLuca, 2005; Na et al., 2005; Park and Na, 2008).
Furthermore, PEGylation of OCT preserved the more stable sec-
ondary structure of OCT. OCT is usually PEGylated at its N-
terminus, not the Lys side chain because the later is essential for
its activity (Na et al., 2003; Na and DeLuca, 2005). The amino acids
sequence Phe7-Trp8 -Lys9-Thr1 in SST and in OCT is essential for
the biological activity. Replacing the L-Trp 8 by enantiomer (D-
Trp 8) might, therefore, increase the biological activity as shown
in Figs. 3 and 5. It was also reported that SST analog agonists are
more stable in vivo when they contain (Phe7-(D)-Trp8-Lys9-Thrl)
(Mather et al., 1992; Macke et al., 1993; Li et al., 2009; Huo
et al., 2012). Many strategies such citrate reduction method of
trichloroauric acid and silver nitrate have been developed to for-
mulate nanoparticles conjugated OCT that can deliver OCT to the
specific intracellular site and elicit a distinct biological effect
(Abdellatif et al., 2015).
2.4. Challenges in nanomedicine formulation for receptor targeting
Many challenges have faced the nanoparticles formulated to
active target specific receptors. SST dose not used for therapeutic
purposes since it has a short plasma half-life than three minutes.
Fig. 4. Chemical structure of somatostatin.
Fig. 5. Amino acids sequence of OCT. Phenylalanine, tryptophan, lysine and
threonine amino acids are essential for receptor binding.
Fig. 6. Chemical structure of somatostatin analogous OCT.
Fig. 3. Amino acids sequence of SST. Phenylalanine, tryptophan, lysine and
threonine amino acids are essential for receptor binding.
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This could be due to rapid proteolytic degradation of amino-
peptidases and endo-peptidases in plasma. This limits its applica-
tions to intravenous administration (Abdellatif et al., 2016). An
additional problem is the rebound effects in terms of hormone
secretion after cessation of therapy. The ability of SST to treat
specific diseases is also limited by potential side effects which
are widespread in different organs (Eriksson et al., 1990). Thus,
the initial excitement and the great interest in SST soon vanished.
A little later, initiatives to synthesize more stable and highly potent
SST analogs with prolonged duration of action such as OCT and VAP
has been investigated (Lamberts et al., 1996). For that reason, SST
itself should be replaced with a highly stable peptide such as
OCT. The plasma half-life of OCT is much higher than that of the
endogenous SST. The elimination of OCT from plasma had an
apparent half-life of 1.7–1.9 h compared to 1–3 min with the nat-
ural hormone (Watt et al., 2008). Specific interaction with OCT at
the N-terminus which is based on the difference in reactivity of
the amino group in the N-terminus (pKa 7.8) and an amino group
in the Lys residue (pKa 10.1) at acidic pH (Wong, 1991). It was
reported that PEGylation of OCT with ALD-mPEG at low pH pro-
duces selectively an N-terminal PEGylated molecule (Kinstler
et al., 1996). Additionally, the main disadvantage of AuNPs is that
these are not detectable by fluorescence in contrast to Qdots.
Although AuNPs have lower toxicity than Qdots, Qdots appear to
be far more superior in cell-based investigations (Frangioni,
2003). Qdots could be used as model particles for targeting drug
delivery and imaging. Another challenge during formulation of
these peptides is that SST has many functional groups which make
it difficult to be selectively conjugated, such as the two Lys resi-
dues. As well as the terminal amino groups of alanine, asparagine,
and tryptophan in SST which also makes SST positively charged at
physiological pH as shown in Fig. 4 (Brown et al., 1990; Surujpaul
et al., 2008).
3. Cellular uptake of nanoparticles
The intracellular delivery of nanoparticles is affected by numer-
ous factors, such as size, charge, types of attached ligand, the
degree of ionization and hydrophobicity (Pang et al., 2002). The
intercellular delivery of nanoparticles to cells could be manifested
through phagocytosis, macropinocytosis, clathrin-mediated endo-
cytosis, caveolae-mediated endocytosis and clathrin-caveolae-
independent endocytosis (Conner and Schmid, 2003; Mayor and
Pagano, 2007; Verma et al., 2008). In addition, there are various
examples of receptor-mediated endocytosis which figured by a
ligand binding to its receptor. AuNPs with different size (14, 50
and 74 nm) and shapes, spheres or rods, were internalized into
Hela cells via a receptor-mediated endocytosis (clathrin-
dependent) (Chithrani et al., 2006). Other studies showed the
internalization of folate conjugated to Folic-PEG-coated-Qdots
was confirmed via receptor-mediated internalization into cells
expressed folate receptors overexpressed in human nasopharyn-
geal cells (KB cells) (Song et al., 2009). Furthermore, Qdots coated
with octreotide and internalized via SSTRs (Abdellatif, 2015),
AuNPs decorated with octreotide for targeting of SSTRs subtype 2
(Abdellatif et al., 2015) and AuNPs coated with SST via electrostatic
attraction internalized via somatostatin receptors have been stud-
ied (Abdellatif et al., 2016).
The cellular uptake of nanoparticles is controlled by the regular
size rules and receptionists within a mammalian cell. The depth of
the plasma membrane bilayer is usually 4–10 nm. Also, the aver-
age sizes of endocytic vesicles in both phagocytosis and pinocyto-
sis pathways for particle internalization are also presented (Mao
et al., 2013). Phagocytes can take up large particles (or nanoparticle
aggregates), opsonized nanoparticles, or particles with certain
ligand alteration via phagocytosis. The accepted mechanism for
nanoparticles internalization in a non-phagocytic mammalian cell
Fig. 7. Schematic drawing for the different types of cellular uptakes of nanoparticles.
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is mostly through pinocytosis or direct diffusion. Moreover, many
different surface modifications, particles can be taken up via speci-
fic (receptor-mediated) endocytosis or nonspecific endocytosis
(Mao et al., 2013). Receptor-mediated endocytosis permits an
import of extracellular large molecules as shown in Fig. 7
(Delehanty et al., 2009; Kelf et al., 2010). In this process, the plasma
membrane is engulfed inwards by specialized membrane micro-
domains forming either clathrin or caveolin-coated pits (Kelf
et al., 2010). However, the specific uptake of nanoparticles via sur-
face receptors can be increased either by direct interactions
between coated particles and receptors or via ligands attached to
nanoparticles (Osaki et al., 2004; Hild et al., 2008; Kelf et al., 2010).
4. Diagnostic purposes of SST
Qdots are semiconductor nanoparticles, with diameters from 1
to 10 nm. The most common Qdots are made of cadmium selenide
coated with zinc sulfide (CdSe/ZnS). Qdots have attracted tremen-
dous interest due to their unique optical properties (Peng and
Peng, 2001; Chan et al., 2002). Qdots have a higher molar extinction
coefficient compared to organic dyes, making them brighter in
photon-limited in vivo studies, which means that they can absorb
light efficiently (Resch-Genger et al., 2008). Furthermore, Qdots
are highly photostable compared to other fluorophores making
them more easy to detect by fluorescence microscopy (Xu et al.,
2012). Qdots are size-tunable and emit light of different wave-
length depending on their size. Larger particles emit lights at the
red end of the visible spectrum, while smaller particles emit at a
shorter wavelength (Kim et al., 2005). Traditional biomedical dyes
are replaced by Qdots due to their unique optical properties like
high brightness and narrow emission bands, to be used as simple
fluorescence materials in bio-imaging (Hutter and Maysinger,
2011; Vibin et al., 2011), immunoassays (Bustos et al., 2012; Zeng
et al., 2012), microarrays, and other applications (Jain, 2003). Fur-
thermore, Qdots are familiar in treatment and imaging of cancer
compared to other nanoparticulatematerials such as AuNPs, carbon
nanotubes, silica nanoparticles, dendrimer, graphene and poly-
meric nanoparticles (Rahman et al., 2012a, 2012b, 2012c).
These FA-PEG-QD functioned as fluorescent nanoprobes that
specifically recognized folate receptors (FRs) overexpressed in
human nasopharyngeal cells (KB cells) but not in an FR-deficient
lung carcinoma cell line (A549 cells). Using confocal fluorescence
microscopy, we demonstrated uptake of FA-PEG-QDs by KB cells
but no uptake of folate-free PEG-QDs. The specificity of this
receptor-mediated internalization was confirmed by comparing
the uptake by KB vs A549 cells. Furthermore, Qdots-loaded
micelles accumulated in the tumor tissue in a passive way (Cao
et al., 2012). In summary, Qdots are a precious tool for cellular
and molecular imaging techniques to diagnose the nature and
stage of cancer and other diseases (Dong and Ren, 2012;
Pericleous et al., 2012).
5. Conclusions
SSTRs are one of the most important G protein-coupled recep-
tors, which are more abundant in different cells and organs. SSTRs
showed a higher expression during cancer development, which is
beneficial in tumor diagnosis as well as in treatment. SST ana-
logues are developed to best fit into the SSTRs and to counteract
the disadvantages of the parent SST. Moreover, they could be con-
jugated to metallic nanoparticles and being actively delivered to
those cells expressing SSTRs with an enhanced efficacy and stabil-
ity. A lot of research and investigations should be performed in the
field of receptor mediated active targeting, which will be an excel-
lent step forward toward different disorders, especially for cancer
treatment.
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